Cardiff Oncology, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CRDF, updated each market day.
CRDF AI Sentiment
AI predicts Cardiff Oncology, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cardiff Oncology, Inc. Common Stock
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Sector
Exchange
Market Cap
$114,169,514
Cap Tier
Employees
31
Headquarters
SAN DIEGO, CA
Listed Since
May 22, 1997
Website
CRDF Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CRDF Volatility
Cardiff Oncology, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
